F730047E07Rik Inhibitors
The chemical class known as Mms22l inhibitors would include compounds that indirectly impact the DNA damage response and homologous recombination repair pathways. These chemicals are not direct antagonists of the MMS22L protein but function by altering cellular processes that MMS22L is critical for.DNA replication inhibitors like Aphidicolin and Hydroxyurea can lead to stalled replication forks, a condition that necessitates homologous recombination for resolution, thereby indirectly challenging MMS22L functionality. Similarly, DNA-damaging agents such as Camptothecin, Etoposide, Cisplatin, and Mitomycin C introduce lesions that require repair via pathways where MMS22L is a key player. The incorporation of nucleoside analogs such as Gemcitabine into DNA can also impede replication and increase the dependency on MMS22L-mediated repair.
Checkpoint kinase inhibitors like UCN-01, VE-821, AZD7762, and KU-55933 disrupt cell cycle regulation and the DNA damage response, which can overload the DNA repair machinery that includes MMS22L. The inhibition of enzymes such as PARP, ATR, Chk1, and ATM by compounds like Olaparib can lead to an increased reliance on homologous recombination repair, where MMS22L operates, thereby indirectly affecting its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
Inhibits DNA polymerase alpha and delta, which are essential for DNA replication where MMS22L functions. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Inhibits Topoisomerase I, leading to DNA damage and potentially increasing demand on MMS22L-mediated repair pathways. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Inhibits Topoisomerase II, causing DNA breaks and challenging MMS22L-involved repair mechanisms. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Inhibits ribonucleotide reductase, depleting dNTPs and stalling replication forks, thereby stressing MMS22L-related repair processes. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Forms DNA crosslinks that require homologous recombination repair, in which MMS22L is implicated. | ||||||
Gemcitabine Hydrochloride | 122111-03-9 | sc-204763 sc-204763A | 25 mg 100 mg | $94.00 $283.00 | 13 | |
Nucleoside analog that incorporates into DNA and halts elongation, impacting MMS22L function indirectly. | ||||||
UCN-01 | 112953-11-4 | sc-202376 | 500 µg | $246.00 | 10 | |
Inhibits checkpoint kinases, possibly compromising cell cycle checkpoints and increasing the load on repair mechanisms involving MMS22L. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Crosslinks DNA and requires homologous recombination for repair, impacting the MMS22L pathway. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
PARP inhibitor, which can lead to an increased reliance on homologous recombination repair, potentially affecting MMS22L. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
ATR inhibitor, which can lead to impaired response to replication stress and influence MMS22L-related processes. | ||||||